课题基金 / 基金详情

项目摘要

项目成果

Jia Zhou的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):据估计,睡眠剥夺和睡眠障碍每年给美国人造成的生产力损失、医疗费用、病假、财产和环境损害超过1000亿美元。嗜睡症是一种致残性疾病,也是理解其他睡眠障碍的关键。猝倒是发作性睡症的另一个主要衰弱症状,估计有60%至90%的发作性睡症患者受到影响。在发现其强大的唤醒作用后的二十年里,莫达非尼已成为治疗嗜睡症和其他睡眠障碍中过度嗜睡的最广泛使用的处方药。尽管莫达非尼具有强大的促醒作用,但它不能抑制猝倒。莫达非尼的这一缺点可能源于它在去甲肾上腺素转运体上缺乏活性,而去甲肾上腺素转运体是几种有效的中风治疗药物的作用部位。结构上与莫达非尼相关的化合物,但在抑制去甲肾上腺素转运体方面表现出新的药理学特征,可能比莫达非尼本身具有更大的治疗价值。Acenta已经建立了一个诺卡因/莫达非尼混合配体的化合物文库,作为选择性单胺转运体抑制剂。这些化合物作为细胞膜多巴胺、去甲肾上腺素和血清素转运体(DAT、NET和SERT)抑制剂的效力各不相同。这些新化合物中的一些是有效的,特异性的DAT抑制剂,而另一些则以大致相同的效力抑制DAT和NET。这些混合化合物的不同药理学特征为发作性睡病和一般睡眠/觉醒障碍的药理学研究提供了强大的资源。通过这笔资金,我们打算跟进我们已经取得的令人兴奋的初步发现,以寻求新的选择性单胺转运蛋白抑制剂作为过度嗜睡和发作性嗜睡-猝厥的潜在治疗方法。本研究计划的具体目的是:1。在现有化合物文库的基础上,将重新合成12个具有适当DAT和NET选择性的有效反式哌啶配体。此外,这些选定的化合物的顺式非对映体也将被合成,并将研究其单胺转运体抑制活性。2. 我们将在下丘脑分泌素/ataxin-3 (hcrt/atax)小鼠的行为和脑电图水平上测量这些选择性良好的化合物的剂量-反应曲线,以抑制睡眠发作和猝倒。3. 临床前ADMET研究将对那些在Aim 2中确定的作为过度嗜睡和发作性睡猝厥的潜在治疗药物最有希望的化合物进行。
英文摘要
DESCRIPTION (provided by applicant): Sleep deprivation and sleep disorders are estimated to cost Americans over $100 billion annually in lost productivity, medical expenses, sick leave, and property and environmental damage. Narcolepsy is a disabling illness and a key to understanding other sleep disorders. Cataplexy is another major debilitating symptom of narcolepsy, and is estimated to affect 60 to 90% of narcoleptic patients. In the two decades since the discovery of its robust wake-promoting effect, modafinil has become the most widely used prescription drug for treatment of excessive sleepiness in narcolepsy and other sleep disorders. Its robust wake-promoting effect notwithstanding, modafinil fails to suppress cataplexy. This disadvantage of modafinil likely stems from its lack of activity at the norepinephrine transporter, the site of action for several potent cataplexy therapeutics. Compounds that are structurally related to modafinil, but exhibit novel pharmacological profiles with respect to norepinephrine transporter inhibition, may be of greater therapeutic value than modafinil itself. Acenta has established a compound library of nocaine/modafinil hybrid ligands that act as selective monoamine transporter inhibitors. The compounds vary in their potency as inhibitors of the cell membrane dopamine, norepinephrine and serotonin transporters (DAT, NET and SERT). Some of these novel compounds are potent, specific DAT inhibitors, while some others inhibit both DAT and NET with roughly equal potency. The diverse pharmacological profiles of these hybrid compounds provide a powerful resource for studies on the pharmacology of narcolepsy and of sleep/wake disorders in general. Through funding from this grant, we intend to follow-up on the exciting preliminary findings we have made with the following specific aims in pursuit of novel selective monoamine transporter inhibitors as potential therapeutics for excessive sleepiness and narcolepsy-cataplexy. The specific aims of this research proposal are: 1. Based on the compound library in hand, 12 potent trans-piperidine ligands possessing appropriate DAT and NET selectivity profiles will be resynthesized. Additionally, the cis-diastereomers of these selected compounds will also be synthesized and their monoamine transporter inhibitory activity will be investigated. 2. The dose-response curves of those selected compounds that exhibit good selectivity will be measured for the suppression of sleep attacks and cataplexy at the behavioral and electroencephalographic levels in hypocretin/ataxin-3 (hcrt/atax) mice. 3. Pre-clinical ADMET studies will be carried out on those compounds showing the greatest promise as potential therapeutics for excessive sleepiness and narcolepsy-cataplexy as determined in Aim 2. Public Health Relevance: Acenta Discovery has developed a compound library of piperidine-based nocaine/modafinil hybrid ligands that act as selective monoamine transporter inhibitors. The diverse pharmacological profiles of these hybrid compounds provide a powerful resource for studies on the pharmacology of narcolepsy and of sleep/wake disorders in general and the potential therapeutics for excessive sleepiness and narcolepsy-cataplexy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Prodrugs of NAAG Peptidase Inhibitors for the Treatment of Schizophrenia
  • 批准号:
    7479074
  • 项目类别:
  • 资助金额:
    $31.99万
  • 财政年份:
    2008
  • 负责人:
    Jia Zhou
  • 依托单位:
NAAG Peptidase Inhibitors for the Treatment of Traumatic Brain Injury
  • 批准号:
    7391894
  • 项目类别:
  • 资助金额:
    $37.94万
  • 财政年份:
    2008
  • 负责人:
    Jia Zhou
  • 依托单位:
Piperidine-Based Compounds as Therapeutics for Narcolepsy-Cataplexy
  • 批准号:
    7465510
  • 项目类别:
  • 资助金额:
    $25.0万
  • 财政年份:
    2007
  • 负责人:
    Jia Zhou
  • 依托单位:
Development of GSK-3 Beta Inhibitors for the Treatment of Parkinson's Disease
  • 批准号:
    7596052
  • 项目类别:
  • 资助金额:
    $28.26万
  • 财政年份:
    2007
  • 负责人:
    Jia Zhou
  • 依托单位:
海外基金